Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation

Last updated: September 12, 2014
Sponsor: Eugene Y Rhee, MD
Overall Status: Trial Status Unknown

Phase

3

Condition

Premature Ejaculation

Treatment

N/A

Clinical Study ID

NCT02241460
Promescent
KPSC IRB 6428
  • Ages > 18
  • Male

Study Summary

The purpose of this study is to evaluate the efficacy of treatment with Promescent Lidocaine Spray compared with placebo in patients with premature ejaculation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject has provided written informed consent before screening.

  • Subject is a male, 18 years of age or older.

  • Subject meets the diagnostic criteria for premature ejaculation as defined by theDSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, TextRevision; 2000).

  • Subject has a stable, monogamous, heterosexual relationship and sexually active for atleast the last 6 months.

  • Subject and partner are willing and able to engage in sexual intercourse.

Exclusion

Exclusion Criteria:

  • Subject has never achieved an intravaginal ejaculation during the past 6 months (i.e.,always ejaculates prior to penetration).

  • Subject has other forms of ejaculatory dysfunction (e.g., retrograde ejaculation,anejaculation, painful ejaculation).

  • In the opinion of the investigator, the subject has a condition or is in a situationthat may put the subject at significant risk, may confound the study results, or mayinterfere significantly with the subject's ability to participate in the study.

Study Design

Total Participants: 120
Study Start date:
March 01, 2014
Estimated Completion Date:
December 31, 2015

Study Description

Promescent Lidocaine Spray is a non-prescription drug that is marketed under an over-the-counter drug monograph (21 CFR Section 348.10 Subpart B (a)(2)) for male genital desensitizing drug products. In addition the evaluating the efficacy of treatment with Promescent, this study will evaluate patients' subjective distress, perception of improvement and optimal dose, and safety and tolerability of Promescent for patients with premature ejaculation and their respective partners.

Connect with a study center

  • Kaiser Permanente

    Los Angeles, California 90027
    United States

    Site Not Available

  • Kaiser Permanente

    San Diego, California 92154
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.